Literature DB >> 27340349

Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.

Feng Wen1, Qiu Li1.   

Abstract

Although monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) have largely enriched the available therapeutic choices for colorectal cancer (CRC), the understanding and management of their associated clinical toxicities are limited. In addition, the combined strategies of administering EGFR mAbs and traditional cytotoxic agents, such as 5-fluorouracil, oxaliplatin and irinotecan, have resulted in a more complicated management of CRC treatment-related side effects compared with EGFR mAb monotherapy. We believe that a thorough recognition of the toxicities of EGFR mAb drugs is essential for physicians to increase the therapeutic index in the treatment of CRC. This review aims to summarize the existing information regarding the treatment dilemmas of cetuximab combined with chemotherapy in the management of metastatic CRC.

Entities:  

Keywords:  Cetuximab; Chemotherapy; Colorectal cancer; Metastatic; Toxicity

Mesh：

Substances：

Year:  2016        PMID： 27340349      PMCID： PMC4910654          DOI： 10.3748/wjg.v22.i23.5332

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  65 in total

Review 1.  Improving the efficacy of antibody-based cancer therapies.

Authors:  P Carter
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

2.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

3.  EGF increases TRPM6 activity and surface expression.

Authors:  Stéphanie Thebault; R Todd Alexander; Wouter M Tiel Groenestege; Joost G Hoenderop; René J Bindels
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

4.  Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

Authors:  Pierpaolo Correale; Monica Marra; Cinzia Remondo; Cristina Migali; Gabriella Misso; Felice Paolo Arcuri; Maria Teresa Del Vecchio; Antonietta Carducci; Lucia Loiacono; Pierfrancesco Tassone; Alberto Abbruzzese; Pierosandro Tagliaferri; Michele Caraglia
Journal:  Eur J Cancer       Date:  2010-06       Impact factor: 9.162

5.  FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.

Authors:  Axel Grothey; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

6.  Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.

Authors:  Ian Krop; Tim Demuth; Tina Guthrie; Patrick Y Wen; Warren P Mason; Prakash Chinnaiyan; Nicholas Butowski; Morris D Groves; Santosh Kesari; Steven J Freedman; Samuel Blackman; James Watters; Andrey Loboda; Alexei Podtelezhnikov; Jared Lunceford; Cong Chen; Maxine Giannotti; Jeremy Hing; Robert Beckman; Patricia Lorusso
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

7.  XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions.

Authors:  A E Vidal; S Boiteux; I D Hickson; J P Radicella
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

8.  Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance.

Authors:  A Harstrick; A Gonzales; N Schleucher; U Vanhoefer; K Lu; J L Formento; G Milano; H Wilke; S Seeber; Y Rustum
Journal:  Anticancer Drugs       Date:  1998-08       Impact factor: 2.248

9.  Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.

Authors:  A Madi; D Fisher; R H Wilson; R A Adams; A M Meade; S L Kenny; L L Nichols; M T Seymour; H Wasan; R Kaplan; T S Maughan
Journal:  Br J Cancer       Date:  2012-08-30       Impact factor: 7.640

10.  Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).

Authors:  J Souglakos; N Ziras; S Kakolyris; I Boukovinas; N Kentepozidis; P Makrantonakis; S Xynogalos; Ch Christophyllakis; Ch Kouroussis; L Vamvakas; V Georgoulias; A Polyzos
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640
View more
  3 in total

Review 1.  Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.

Authors:  Celia N Sanchez-Dominguez; Hugo L Gallardo-Blanco; Mauricio A Salinas-Santander; Rocio Ortiz-Lopez
Journal:  Exp Ther Med       Date:  2018-05-18       Impact factor: 2.447

2.  A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents.

Authors:  Nikunj B Bhatt; Darpan N Pandya; Stephanie Rideout-Danner; Howard D Gage; Frank C Marini; Thaddeus J Wadas
Journal:  Dalton Trans       Date:  2018-09-04       Impact factor: 4.390

3.  Evaluation of the effect of 2-(2,4-dihydroxyphenyl)-4H-benzofuro[3,2-d][1,3]thiazin-4-one on colon cells and its anticancer potential.

Authors:  Arkadiusz Czerwonka; Marta K Lemieszek; Monika Karpińska; Joanna Matysiak; Andrzej Niewiadomy; Wojciech Rzeski
Journal:  Med Chem Res       Date:  2018-07-25       Impact factor: 1.965
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.